May 2004 Table of Contents

External Link - article-94607.pdf

Articles in this issue

about 22 years ago

Article

The Risk Management Mandate

about 22 years ago

Article

Partners in Learning

about 22 years ago

Article

Early Warnings

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

The Gates Foundation: Perfectly Aligned Interests

ByNicholas Jacobus,Sandra Coufal, MD

May 18th 2026

FDA’s New Pilot Program and Real-Time Review of Clinical Data

ByMike Hollan,Dr. Richard Graham

May 18th 2026

Politics, Capital Markets, Misinformation and the Impact on Biotech: Q&A with Jeremy Levin

ByMike Hollan,Dr. Jeremy Levin

May 18th 2026

How Pharma is Adjusting Strategies for Changing Dynamics at FDA

ByMike Hollan,David Crean

May 18th 2026

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

ByNicholas Jacobus

May 15th 2026

May 2004 Table of Contents

Articles in this issue

Related Content

The Gates Foundation: Perfectly Aligned Interests

FDA’s New Pilot Program and Real-Time Review of Clinical Data

Politics, Capital Markets, Misinformation and the Impact on Biotech: Q&A with Jeremy Levin

How Pharma is Adjusting Strategies for Changing Dynamics at FDA

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

Trending on PharmExec

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

John Oyler: Rewiring Operations in Oncology

Beyond the Molecule: The New Competitive Battlefield in Oncology

The Relationship Between the Capital Markets and Biotech?

FDA Places Full Clinical Hold on Aardvark Therapeutics’ ARD-101